Don't let it fade away how fortunate an ICI is for
Post# of 155643

Also from the new Our Science:
"leronlimab allows the host immune system (CD8+ cells) to identify the cancer cells as a threat and attack them in what has now become a “hot” or inflamed microenvironment (expressing various inflammatory cytokines).".....& this too:
"leronlimab alone has demonstrated anti-metastatic activity by blocking CCR5-mediated signaling pathways that are known to facilitate tumor cell migration, invasion, and the establishment of metastatic niches."
1 other huge advantage Leronlimab brings to any LL / ICI combo --- no drug-drug interaction from LL.
The strength of any ICI is free to fully hit tumors, thanks to LL...( ICI market consolidation ?? )
___
* Wouldn't it be something...if:
LL increases the treatable population from 15% to "100%",, & the new ICI dosing is actually lower, than the current regiment for the"15%"...
LL's total profile absolutely makes it a possibility.
Wowzer,,,, the medical world would say....

